R
Ronald G. Stoller
Researcher at University of Pittsburgh
Publications - 49
Citations - 3261
Ronald G. Stoller is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Veliparib & Cancer. The author has an hindex of 21, co-authored 47 publications receiving 3069 citations.
Papers
More filters
Journal ArticleDOI
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
Jeffrey Crawford,Howard Ozer,Ronald G. Stoller,David H. Johnson,Gary H. Lyman,Imad A. Tabbara,Mark G. Kris,John Grous,Vincent J. Picozzi,Gregory Rausch,Roy E. Smith,William J. Gradishar,Anne M. Yahanda,Martha Vincent,Morgan Stewart,John A. Glaspy +15 more
TL;DR: A randomized clinical trial to test the hypothesis that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients with cancer and the clinical implications.
Journal ArticleDOI
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
Jeffrey Crawford,Howard Ozer,Ronald G. Stoller,David H. Johnson,Gary H. Lyman,Imad A. Tabbara,Mark G. Kris,John Grous,Vincent J. Picozzi,Gregory Rausch,Roy E. Smith,William J. Gradishar,Anne M. Yahanda,Martha Vincent,Morgan Stewart,John A. Glaspy +15 more
TL;DR: The use of G-CSF as an adjunct to chemotherapy in patients with small-cell cancer of the lung was well tolerated and led to reductions in the incidence of fever with neutropenia and culture-confirmed infections, and in the total number of days of treatment with intravenous antibiotics and days of hospitalization.
Journal ArticleDOI
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors
Jordi Rodon,Hussein Tawbi,Anne L. Thomas,Ronald G. Stoller,Christian P. Turtschi,José Baselga,John Sarantopoulos,Devalingam Mahalingam,Yaping Shou,Melissa A. Moles,Lin Yang,Camille Granvil,Eunju Hurh,Kristine Rose,Dereck Amakye,Reinhard Dummer,Alain C. Mita +16 more
TL;DR: Sonidegib has an acceptable safety profile in patients with advanced solid tumors and exhibits antitumor activity in advanced BCC and relapsed medulloblastoma, both of which are strongly associated with activated hedgehog pathway, as determined by gene expression.
Journal ArticleDOI
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
Suresh Ramalingam,Robert A. Parise,Ramesh K. Ramananthan,Theodore F. Lagattuta,Lori A. Musguire,Ronald G. Stoller,Douglas M. Potter,Athanassios Argiris,James A. Zwiebel,Merrill J. Egorin,Chandra P. Belani +10 more
TL;DR: Both schedules of vorinostat were tolerated well in combination with carboplatin and paclitaxel, and encouraging anticancer activity was noted in patients with previously untreated non–small cell lung cancer.
Journal ArticleDOI
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer
Brian A. Boone,Jennifer Steve,Alyssa M. Krasinskas,Amer H. Zureikat,Barry C. Lembersky,Michael K. Gibson,Ronald G. Stoller,Herbert J. Zeh,Nathan Bahary +8 more
TL;DR: Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine‐based regimens and there is currently limited experience with neoadjuvant FolFIRinoX in Pancreatic cancer.